You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Novartis to fund oral skin cancer drug
Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility
#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability
Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles
Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018
Ligand Pharmaceuticals Inc. is partnering with Novartis AG to develop a liquid formulation of Trametinib using its Captisol technology.
Trametinib is used to treat a certain type of skin cancer with Captisol designed to optimize the solubility and stability of drugs.
Novartis will fund the program in exchange for commercialization rights. Ligand will receive an undisclosed license fee as well as royalties on future sales as a result of the agreement.